People In Brief
This article was originally published in The Gray Sheet
Executive Summary
Abiomed resignation: Chief Financial Officer Daniel J. Sutherby left the cardiac assist device firm Oct. 1, according to an Oct. 2 Securities and Exchange Commission filing, which identifies Ian McLeod, Abiomed's corporate controller, as acting CFO. On the following day, the company reaffirmed its fiscal year 2009 revenue guidance of $75-$80 million, up from $58.9 million in fiscal 2008. While the resignation is "not ideal," said Morgan Stanley device analyst David R. Lewis, it is probably more reflective of changing strategic needs in the company following the June launch of the Impella 2.5 assist device (1"The Gray Sheet" June 9, 2008, p. 20), rather than "any ominous development.
You may also be interested in...
Abiomed Markets Impella 2.5 Cardiac Assist Device To Cath Labs
Abiomed is targeting its Impella 2.5 cardiac assist device at the top 300 interventional cardiology labs in the United States, firm CEO Michael Minogue said in a June 2 conference call announcing the market launch
Covidien Faces Challenge Of Accelerating Growth After Spin-Off From Tyco
Newly independent medical technology firm Covidien plans select acquisitions and divestitures as well as increased licensing activity to help accelerate growth following its June 29 spin-off from parent company Tyco International
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.